ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Hot Features

Registration Strip Icon for discussion Register to chat with like-minded investors on our interactive forums.

ALIM Alimera Sciences Inc

3.49
0.18 (5.44%)
27 Apr 2024 - Closed
Delayed by 15 minutes
Share Name Share Symbol Market Type
Alimera Sciences Inc NASDAQ:ALIM NASDAQ Common Stock
  Price Change % Change Share Price Bid Price Offer Price High Price Low Price Open Price Shares Traded Last Trade
  0.18 5.44% 3.49 3.33 4.30 3.50 3.28 3.28 17,332 01:00:00

Alimera Sciences to Report Fourth Quarter 2016 Financial Results on March 1, 2017

23/02/2017 4:24pm

GlobeNewswire Inc.


Alimera Sciences (NASDAQ:ALIM)
Historical Stock Chart


From Apr 2019 to Apr 2024

Click Here for more Alimera Sciences Charts.

Alimera Sciences (NASDAQ:ALIM), a leader in research, development and commercialization of prescription ophthalmic pharmaceuticals, today announced that it will release its financial results for the fourth quarter and year ended December 31, 2016, after the close of the financial markets on March 1, 2017.

An accompanying conference call will be hosted by Dan Myers, Chief Executive Officer and Rick Eiswirth, President and Chief Financial Officer to discuss the results. The call will be held at 10:00 AM ET, on Thursday, March 2, 2017. Please refer to the information below for conference call dial-in information and webcast registration.

Conference Details

Conference date: Thursday, March 2, 2017, 10:00 AM ET

Conference dial-in: 877-269-7756

International dial-in: 201-689-7817

Conference Call Name: Alimera Sciences' Fourth Quarter 2016 Results Call

Webcast Registration: Click Here

Following the live call, a replay will be available on the Company's website, www.alimerasciences.com, under "Investor Relations".

About Alimera Sciences

Alimera Sciences, founded in June 2003, is a pharmaceutical company that specializes in the research, development and commercialization of prescription ophthalmic pharmaceuticals. Alimera is presently focused on diseases affecting the back of the eye, or retina, because these diseases are not well treated with current therapies and will affect millions of people in our aging populations. Alimera’s commitment to retina specialists and their patients is manifest in its product and development portfolio designed to treat early- and late-stage diseases. For more information, please visit www.alimerasciences.com.

Contact:
CG Capital
877.889.1972
investorrelations@cg.capital

1 Year Alimera Sciences Chart

1 Year Alimera Sciences Chart

1 Month Alimera Sciences Chart

1 Month Alimera Sciences Chart

Your Recent History

Delayed Upgrade Clock